Akero was founded to develop transformational treatments for people with metabolic dysfunction-associated steatohepatitis (MASH) and other serious metabolic diseases marked by high unmet medical need.

We began with an engineered protein called efruxifermin (EFX), which is in phase 3 clinical trials for the treatment of MASH. MASH is a serious liver disease caused by metabolic dysregulation with few treatment options. We believe restoring whole-body metabolic balance is the key to addressing metabolic dysregulation and bringing impactful therapeutic options to people with serious metabolic diseases—and that EFX is ideally suited for this challenge.

In 2025, Novo Nordisk acquired Akero to unlock the full potential of EFX and extend its reach to more people living with MASH.